556 related articles for article (PubMed ID: 22433752)
1. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL
Value Health; 2012; 15(2):217-30. PubMed ID: 22433752
[TBL] [Abstract][Full Text] [Related]
2. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
[TBL] [Abstract][Full Text] [Related]
3. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
4. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
Berger ML; Mamdani M; Atkins D; Johnson ML
Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
[TBL] [Abstract][Full Text] [Related]
5. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
Mullins CD; Sanchez RJ
J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
[TBL] [Abstract][Full Text] [Related]
6. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
[TBL] [Abstract][Full Text] [Related]
7. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
[TBL] [Abstract][Full Text] [Related]
9. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
11. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness research: guidelines for good practices are just the beginning.
Johnson ML; Chitnis AS
Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):51-7. PubMed ID: 21351858
[TBL] [Abstract][Full Text] [Related]
13. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
Caro JJ; Briggs AH; Siebert U; Kuntz KM;
Value Health; 2012; 15(6):796-803. PubMed ID: 22999128
[TBL] [Abstract][Full Text] [Related]
14. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness.
Roche N; Reddel H; Martin R; Brusselle G; Papi A; Thomas M; Postma D; Thomas V; Rand C; Chisholm A; Price D;
Ann Am Thorac Soc; 2014 Feb; 11 Suppl 2():S99-104. PubMed ID: 24559028
[TBL] [Abstract][Full Text] [Related]
15. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
[TBL] [Abstract][Full Text] [Related]
16. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.
Matza LS; Patrick DL; Riley AW; Alexander JJ; Rajmil L; Pleil AM; Bullinger M
Value Health; 2013 Jun; 16(4):461-79. PubMed ID: 23796280
[TBL] [Abstract][Full Text] [Related]
17. Some methodological points to consider when performing systematic reviews in comparative effectiveness research.
Berlin JA; Cepeda MS
Clin Trials; 2012 Feb; 9(1):27-34. PubMed ID: 22049086
[TBL] [Abstract][Full Text] [Related]
18. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
Jaime Caro J; Eddy DM; Kan H; Kaltz C; Patel B; Eldessouki R; Briggs AH;
Value Health; 2014 Mar; 17(2):174-82. PubMed ID: 24636375
[TBL] [Abstract][Full Text] [Related]
19. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966
[TBL] [Abstract][Full Text] [Related]
20. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]